Non-Hodgkin’s Lymphoma

yes, @eye4msu that is the trick- who is still at high risk so they get Paxlovid & boosters. My father is 88 s/p chemo for B cell lymphoma & did fine with COVID but we boosted & gave him Paxlovid - that is what I mean (@MonicaGandhi9)

Suffering "Diffuse large B-cell lymphoma" ZEBA TAHSIN 16Y my daughter. advice to survive properly (@MdZahid1974)

suffering NON HODGKIN LYMPHOMA, stage-4 (@MdZahid1974)

To better understand diffuse large B-cell lymphoma, MyLymphomaTeam spoke with @timfenske, a hematologist and medical oncologist who specializes in lymphoma. Read more:https://t.co/203m0fv92w (@MyLymphomaTeam)

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma | NEJM https://t.co/Qa0JdrrrmH #bmtsm #lymsm @Lymphoma_Doc (@Transplant_Doc)

👉🏽7/10 invited manuscript by @WomenInLymphoma for #HematologicalOncology @icmlugano "Diffuse large B-cell lymphoma" 🔗https://t.co/1Ox6UZzXyk #lymsm #lymphoma #DLBCL @lymphomaOz @DrElizaHawkes @SehnLaurie @SoniSmithMD @AllisonBarra1 (@WomenInLymphoma)

68 years, Primary CNS lymphoma, bed-ridden *IELSG SCORE- 4* To treat or not? And how to treat? @bagalbp @RanjitKSMD @shaunak_3 @drvineetgovinda (@Doc_Amarendra)

B-cell lymphoma? (@theTpusk)

This is Rupi and me today. We started chemo together 10 yrs ago for Non Hodgkins and met up to celebrate 10 years since finishing it. @nottmhospitals @DrChrisPFox @Dr_Andy_Haynes @NUHCharity @NonHodgkinLym @survivor @cancerfighter @healthy (@karriecourtney)

Seit dem 3. Juli 2023 sind die spannenden Ergebnisse vom #EHA2023 online. https://t.co/dBRoi97ix4 #patientstoday #ehealth #CLL #NHL #multiplesmyelom #hematology #oncology #Krebsinformationsdienst #DKFZ (@JohannesFoerner)

Hey Dr. @ASkarbnik we did it! Backpacked with Tyler’s troop in New Mexico, climbed 3,550 feet from trailhead to top of 10,250-foot mountain three years after rolling into the hospital unable to stand or walk because of non-Hodgkins. THANK YOU for making this week possible! (@ChrisDolack)

I would say: “Low grade lymphoma to be classified, with differential diagnosis on Mantle Cell, Follicular and other NHL”. 🤟🏻 (@PinUpdOk)

As a stage 4 primary testicular Non-Hodgkin lymphoma #cancer survivor & thriver, I am grateful to have the best brilliant/warm/compassionate oncologist in the world @SoniSmithMD @UCCancerCenter @UChicagoMed https://t.co/godq8S7547 (@mwalno)

Autologous stem cell transplants, or ASCT, have been the gold standard for relapsed B cell lymphoma. “We now have data showing that CAR T cell therapy is preferred over ASCT,” says @ChrisRFlowersMD. https://t.co/gBqLFWPlSh @AJMC #lymphoma #EndCancer (@MDAndersonNews)

What are the recent developments in treating diffuse large B cell lymphoma? And what novel therapies are on the horizon? Our Dr. Loretta Nastoupil shares her insights in this interview: https://t.co/K2vpfFyZjs @medpagetoday @LNastoupilMD #lymphoma #EndCancer (@MDAndersonNews)

Yes, that’s the entire idea of categorizing the disease as being related to alcohol or not. Should we get rid of nonmaleficence? Non-Hodgkin's lymphoma? (@DanClintonRN)

Same, that’s how we guessed it, lol!! Anaplastic large cell lymphoma—had to be talking about ALK (@HemeOncUofl)

Oncology master level supplemental question @AaronGoodman33 Which gene can be altered in a significant subset of each of these cancers? Inflammatory breast NSCLC Anaplastic large cell lymphoma Neuroblastoma Spitzoid melanoma Inflammatory myofibroblastic tumor (@Dr_R_Kurzrock)

Zilovertamab vedotin was tolerable and generated early efficacy signals in patients with relapsed/refractory non-Hodgkin lymphoma. @michaelwangmd @MDAndersonNews @icmlugano #17ICML #lymsm https://t.co/l8QPz09JUb (@OncLive)

Non-Hodgkin's lymphoma (@VanitaNoronha)

Follicular lymphoma (FL), a rare blood cancer of the lymphatic system, is one type of non-Hodgkin lymphoma. To learn more about follicular lymphoma, MyLymphomaTeam spoke with hematologist @timfenske. Watch some of his insights:https://t.co/7mr4ulWUpQ (@MyLymphomaTeam)

Duvelisib led to a high response rate in patients w/ peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma. @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/v5J1uSXhsl (@OncLive)

Liso-cel demonstrated a manageable safety profile and could serve as a potential new treatment option for mantel cell lymphoma patients, says our Dr. Michael Wang of the TRANSCEND NHL 001 trial he led. https://t.co/qEfSWfSh4P @TargetedOnc @michaelwangmd #17ICML #EndCancer (@MDAndersonNews)

Novel ADC Delivers Responses and a Manageable Safety Profile in R/R Non-Hodgkin Lymphoma @michaelwangmd @MDAndersonNews @icmlugano #17ICML #lymsm https://t.co/kmO8WUYJrU (@OncLive)

Three of my cousins have had chemotherapy extend their lives for ten years plus...and they had/have a great quality of life. One cousin had her non hodgkins lymphoma come back and she died from it but it was 18 yrs later (@babymama0drama)

Duvelisib led to a high response rate in patients w/ peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma. @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/TJCxD8CBUh (@OncLive)

TRANSCEND NHL 001 Liso-cel for mantle cell lymphoma @michaelwangmd #17ICML - 88 pts - median 3 prior lines - 94% prior BTKi - 23% TP53mut - 8% CNS disease (@Eddie_Cliff)

1st report antiCD19 CART Liso-cel in r/r mantle cell lymphoma (>1 prior line). TRANSCEND NHL 001 @michaelwangmd Astonishing results (even although influenced by Covid pandemia) & better safety profile related with CRS/neurologic than which reported with brexu-cel #LBA3 #17ICML (@Fer_martinmoro)

Bone Marrow Assessment may be Omitted in Newly Diagnosed Diffuse Large B-Cell Lymphomas with Primary CNS Involvement 🧠 -> ❌🦴 #295 https://t.co/OLBa9pOJWD (with @j_marquet and Patricia Lopez) (@Fer_martinmoro)

Our NEW Primer on Primary central nervous system lymphoma is live today! By Ferreri, Calimeri, @CwynKate, Dietrich, Grommes, Hoang-Xuan, Hu, @GeraldIllerhaus, Nayak, Ponzoni & Batchelor. Check it out here: https://t.co/oHHPzc3lmu (@DiseasePrimers)

Here, Adam Olszewski, MD, discusses the role of CNS prophylaxis in the treatment of aggressive B-cell lymphoma, which he shared in a debate at the 2023 Great Debates & Updates in Hematologic Malignancies meeting #GDUHem. https://t.co/bN8BX1eUwj @lymphomatic @GreatDebatesCME (@OncLearnNetwork)

#17ICML P Ghione: Career women of BRCA1/2 mutations are at 12-times higher of developing a breast-implanted associated anaplastic large cell lymphoma #lymsm (@DrRaulCordoba)

Excellent presentation by @ivana_spasevska today at #17ICML, presenting our study Diversity of immunosuppressive regulatory T cells in B-cell lymphoma @Kreftforeningen @forskningsradet @Oslounivsykehus (@LabMyklebust)

Fascinating talk by Kuppers. • est that cHL is a B-cell lymphoma • but down regn of B-cell phenotype • multiple mechm- epigenetic, down regn of B-cell transcripn factors • this is prob important part of pathogen (not epiphenomenon) The HRS is full of surprises! #17ICML (@graham74GC)

Mediastinal RT can be safely omitted in primary mediastinal B-cell lymphoma patients with complete metabolic response after frontline [126 patients needed to be consolidated with RT to have PFS benefit in 1 patient] #17ICML (@Fer_martinmoro)

Important data showing the value of ASCT in primary CNS lymphoma patients. #17ICML (@Dr_Daniel_Molin)

It's wonderful that a randomized study showed an OS difference in R/R DLBCL and we have a CAR-T era. My point was that the introduction of rituximab immediately changed the natural history of B-cell lymphoma. (@MaurerStats)

Full house at Educational Session on Diffuse Large B-cell Lymphoma at #17ICML. What a privilege to learn from the best in the field #lymsm (@DrRaulCordoba)

CAR T‐cell therapy in large B cell lymphoma by ⁦@gilles_salles⁩ at the ⁦@icmlugano⁩ #17icml https://t.co/g0A3yRRtnI (@frbertoni)

Ich habe gelesen, dass Non-Hodgkin überwiegend bei älteren Patienten vorkommt. Meine Schwester ist 46 und bei ihr wurde es diagnostiziert. Kann man da was zu Chancen sagen, ob sie wieder gesund werden kann? (@Frau_keMann)

PRESENTATION ID S229 PROPHYLACTIC EFFICACY OF INTRATHECAL VERSUS INTRAVENOUS METHOTREXATE FOR CNS RELAPSE IN HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA : A PHASE III RANDOMIZED, CONTROLLED STUDY #EHA23 #lymsm (@smbenlazar)

Case Report: #IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma https://t.co/FIkL7efHKb @RajaAtreya #MarkusNeurath #SebastianZundler @Y_ECCO_IBD @fgomollon @IBD_FloMD @GianlucaPellino @DCharabaty @DignassAxel @Iris_Dotan @alearmuzzi @EdwardLoftus2 (@BettenworthDb)